Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates

Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current vaccines under development such as protein vaccines, adjuvant protein vaccines, viral vector vaccines and mRNA vaccine candidates.

The abstract entitled: ‘Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age‘ (Abstract #LB745)’ was presented at IDWeek 2022, 19-23 October 2022.

Interviews available in this series:

Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results

Highlights from IDWeek 2022

Questions:

1. Could you give us a brief overview of the health burden of respiratory syncytial virus (RSV) infection in older adults? (0:14)
2. Why has it proven so difficult to develop a vaccine for RSV? (1:08)
3. What vaccine candidates are currently in development? (2:01)

Disclosures: Michael Ison receives grant/research support from GSK.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek 2022